Decision Resources acquires Manhattan Research

Share this article:

Decision Resources announced the acquisition of Manhattan Research on June 17.  The move will expand Decision Resources' global physician and consumer digital market research portfolio, according to a statement.  Terms of the deal were not disclosed to the public.

“Part of Decision Resources' big goal is to grow our business both organically, and to build a stable of premier market research firms that focus on specific areas of the healthcare industry,” said Elizabeth Marshall, director of marketing at Decision Resources.  Marshall cites Millennium Research Group and HealthLeaders as two examples of other research firms providing Decision Resources with a specialized focus: Millennium for medical devices and technology, and HealthLeaders for managed care.  “We're looking at the bigger picture and the healthcare industry as a whole – we're offering clients an integrated model,” says Marshall.  

Manhattan Research will remain headquartered in New York, NY.  Decision Resources is located in Waltham, MA.  Other companies owned by Decision Resources include Arlington Medical Resources, which was acquired last December, and Fingertip Formulary, acquired in March. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...